Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795412 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumours, sponsored by Pyxis Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 15
- Study locations
NCT06795412: Recruiting Phase 1 study of Advanced Solid Tumours, sponsored by Pyxis Oncology.
NCT06795412 is a Phase 1 study of Advanced Solid Tumours that is actively recruiting participants, run by Pyxis Oncology. The registered enrollment target is 220 participants, above the 187-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (18% higher). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06795412, a Phase 1 study of Advanced Solid Tumours, is actively recruiting participants, sponsored by Pyxis Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 15
- Study locations
Study Summary
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG PYX-201
Study Locations (15)
Madrid
- Hospital Universitario Ramón y Cajal - Madrid
- START Madrid - Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Universitario 12 de Octubre - Madrid
California
- University of California San Diego - San Diego
- Sarcoma Oncology Center - Santa Monica
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- University of Texas - M.D. Anderson Cancer Center - Houston
- NEXT Oncology Houston - Houston
Florida
- Moffitt Cancer Center - Tampa
Virginia
- NEXT Virginia - Fairfax
Barcelona
- Hospital Universitario Vall d'Hebron - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2027-12-06 |
| Phase | Phase 1 |
What NCT06795412 shows while recruiting
NCT06795412 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 187-participant average among 3 other Advanced Solid Tumours trials with a reported enrollment target (18% higher).
The record links to 1 condition, with Advanced Solid Tumours appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT06795412 lists 15 locations in 9 states (Madrid, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06795412 about?
NCT06795412 is a clinical study titled "Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors". The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
What is the current status of trial NCT06795412?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2025-04-15. Estimated completion is 2027-12-06.
What conditions does trial NCT06795412 study?
This clinical trial studies the following conditions: Advanced Solid Tumours.
What interventions are being tested in trial NCT06795412?
The interventions under investigation include: pembrolizumab (DRUG), PYX-201 (DRUG).
Who is sponsoring clinical trial NCT06795412?
This trial is sponsored by Pyxis Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795412 being conducted?
This trial has 15 study locations across California, Florida, Massachusetts, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI